F M Investments LLC Sells 283 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

F M Investments LLC lowered its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 0.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 72,462 shares of the company’s stock after selling 283 shares during the period. F M Investments LLC owned about 0.22% of TransMedics Group worth $11,377,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the company. Vanguard Group Inc. increased its holdings in TransMedics Group by 2.8% during the fourth quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company’s stock valued at $147,214,000 after buying an additional 50,673 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of TransMedics Group by 5.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company’s stock valued at $94,061,000 after acquiring an additional 30,092 shares during the period. State of Alaska Department of Revenue purchased a new stake in shares of TransMedics Group in the 3rd quarter worth $2,560,000. Deerfield Management Company L.P. Series C bought a new position in TransMedics Group in the 2nd quarter worth $1,400,000. Finally, Handelsbanken Fonder AB increased its holdings in TransMedics Group by 657.6% in the 3rd quarter. Handelsbanken Fonder AB now owns 64,400 shares of the company’s stock worth $10,111,000 after acquiring an additional 55,900 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

TMDX has been the topic of a number of analyst reports. Robert W. Baird lowered their target price on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a research note on Tuesday. Needham & Company LLC cut their target price on TransMedics Group from $208.00 to $109.00 and set a “buy” rating for the company in a research report on Tuesday. JPMorgan Chase & Co. lowered their price target on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a report on Tuesday. Piper Sandler reaffirmed an “overweight” rating and set a $180.00 price objective on shares of TransMedics Group in a report on Tuesday. Finally, Oppenheimer decreased their price target on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a research note on Tuesday. One analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, TransMedics Group presently has a consensus rating of “Buy” and an average price target of $144.80.

TransMedics Group Trading Up 0.5 %

TransMedics Group stock traded up $0.43 during trading hours on Friday, hitting $82.40. The company had a trading volume of 1,818,675 shares, compared to its average volume of 1,961,312. The company has a debt-to-equity ratio of 2.42, a quick ratio of 8.48 and a current ratio of 8.20. The firm has a market cap of $2.77 billion, a P/E ratio of 87.66 and a beta of 2.08. The company has a 50-day moving average price of $140.51 and a two-hundred day moving average price of $139.29. TransMedics Group, Inc. has a 1 year low of $38.13 and a 1 year high of $177.37.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). The firm had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. TransMedics Group’s quarterly revenue was up 63.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.12) earnings per share. On average, sell-side analysts anticipate that TransMedics Group, Inc. will post 1.08 earnings per share for the current year.

Insider Activity

In related news, insider Anil P. Ranganath sold 4,289 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $152.20, for a total transaction of $652,785.80. Following the sale, the insider now owns 8,893 shares of the company’s stock, valued at $1,353,514.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $9,457,269.06. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Anil P. Ranganath sold 4,289 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $152.20, for a total transaction of $652,785.80. Following the transaction, the insider now owns 8,893 shares in the company, valued at approximately $1,353,514.60. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 61,247 shares of company stock worth $9,518,181. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.